INTRODUCTION
Therapeutic advance in the clinical treatment of B-cell lymphoma has taken advantage from the development of targeted therapy based on monoclonal antibodies (MAbs), including CD20, CD22, and CD52, which target cell surface receptors of neoplastic cells 1 . Therapeutic MAbs have been shown to be effective either alone, or in combination with chemotherapeutics, and as vehicle to deliver radionuclides or toxins to neoplastic cells. However, the effectiveness of therapeutic MAbs is limited by their extended half-life and toxicity as a consequence of non-specific binding to the reticuleendothelium and to unaffected organs, including the bone marrow 2 . This drawback is critical in the case of antibodies used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to tumour sites.
Hence, although the introduction of therapeutic MAbs has broadened the treatment options for subjects with B-cell lymphoma, a substantial number of patients experience a clinical relapse as a consequence of a lack or poor response to the treatments. This grim picture calls for new strategies to improve the in vivo detection and treatment of neoplastic B cells.
As compared to antibodies, peptides are attractive alternatives for cell targeting and in vivo cancer imaging and therapy. Indeed, peptides, which are considerably smaller than antibodies and antibody fragments, do not bind to the reticule-endothelium and do not elicit a significant immune response upon repeated inoculation 3 . Peptides with blocked N-or C-terminus may acquire a cyclic, constrained conformation, and may include unnatural and D-amino acids that allow an extended half-life in vivo. Also, peptides are endowed with several functions, including multi-valence for target moieties and cargo delivery, including radionuclides, cytotoxic drugs and toxins that target cell surface receptors of cancer cells. Examples of tumor-specific peptides include somatostatin 4 and bombesin/gastrin-releasing peptide (BN/GRP) 5 , which exhibit high affinities for the cognate cell-surface receptors. Peptides also facilitate the transport of cytotoxic compounds and stretches of nucleic acid into specific tumor tissues 6 .
Random Peptide Libraries (RPLs) allow the selection of therapeutic peptides for tumor cell surface receptors 7 . RPLs express a large collection of peptide sequences (10 8 
or more) that mimic
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From both linear and conformational epitopes of folded protein domains, which are displayed in multiple copies fused to phage coat proteins 8, 9 . In addition, the linear or conformational epitopes displayed on phages can be translated in short cyclic peptides with little or no loss of binding specificity 10, 11 .
The hypervariable regions (idiotypes) of the surface immunoglobulin (Ig) B-cell receptor (Ig-BCR) expressed by lymphoma cells result from the rearrangement of the Igs genes and are unique for a given clonal B cell population. In this settings, the idiotypic determinants of the Ig-BCR expressed by lymphoma cells function as a specific tumor antigens that may be exploited for cell-specific targeted therapy 12 . Previous studies using RPLs identified peptides (Id-peptide) that exhibited anti-tumor activity against human and murine B-lymphoma by triggering apoptosis of target cells in vitro when administered as dimers or tetramers 13, 14 .
In this study, we evaluated the tumor targeting properties of an Id-peptide, which was selected from RPLs by using as a bait the Ig-BCR of the highly aggressive murine A20 Blymphoma 15, 16 . The RPL-selected Id-peptide specifically bound the A20 cells both in cell cultures and in A20-engrafted syngenic immune competent mice, as shown by FACS, confocal microscopy and positron emission tomography (PET). Cross-linking of the A20 BCR with Id-peptide resulted in the massive apoptosis of targeted cells in vitro by a caspase-dependent mechanism. Consistently, inoculation of the Id-peptide in A20-engrafted mice caused apoptosis of tumor cells and resulted in tumor growth inhibition and extended survival of diseased animals. Since apoptotic tumor cells are source of antigens for the immune system 17 , we also performed an extensive analysis of tumor microenvironment to evaluate the impact of Id-peptide treatment on tumor immunity. Indeed, the Id-treatment reverted the immunosuppressive characteristics of the tumor microenvironment and stimulated a tumor-specific CD8 + T cell activity that contributed to the peptide-driven anti-tumor activity.
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MATERIALS AND METHODS

Cell lines, immunoglobulin purification and peptides.
The A20 and 5T33MM cell line growth conditions are reported in Supplemental Data. The A20-Ig was purified from the culture supernatants by using the Mab Trap TM antibody purification Kit (GE Healthcare). All peptides were purchased from Caslo laboratory ApS, Lyngby, Denmark. The amino acid sequence of the control scrambled peptide (pCNT) was: DQEWCKTISFEPCLEN.
Generation and screening of RPLs. We generated two RPLs consisting of nona-peptides (f88-C7C) and dodeca-peptides (f88-12) displayed on the N-terminus of pVIII major coat protein of filamentous bacteriophage f88-tet, as previously described 9, 18 . A third f88-Cys6 RPL was a kind gift of G.P. Smith 18 . Screening was performed by using A20-Ig purified from culture supernatants.
Details for constructions and screening of RPLs, as well as ELISA procedures are reported in Supplemental Data.
Peptide binding.
Binding of peptides to purified immunoglobulins, mice sera or cells, and competitive peptide binding inhibition were evaluated by ELISA and described in Supplemental Data.
Cell viability, cell cycle and apoptosis. A20 cells (2 x 10 7 /ml) were incubated with biotinylated peptides (20 μg/ml). For peptide tetramerization, streptavidin (100 μg/ml) was added to the cell cultures. Cell viability was determined by trypan blue dye exclusion; apoptosis was measured by Annexin V-FITC staining (Apoptosis Kit, Miltenyi Biotec) and cell cycle was analyzed by using CycleTest Plus DNA Reagent Kit (BD Biosciences); Caspases activities were measured by luminometric assay (Promega Corporation).
Histological analysis.
Detailed procedure for histological evaluation of metastasis, apoptosis and 
RESULTS
Identification of peptide ligands of the A20 monoclonal immunoglobulin.
To identify peptide ligands of surface IgG (sA20-Ig) of A20 B-lymphoma cell line 15, 16 we screened three f88 phage-displayed RPLs using as bait purified A20-Ig, as previously reported 9, 19 . After three rounds of panning with A20-Ig, 22 phage clones, which tested positive for A20-Ig binding in ELISA, were selected (Table 1) ; among these, A20-1, A20-6 and A20-36 showed the highest binding affinities to A20-Ig (Fig. 1A, left panel) . Synthetic peptides pA20-1, pA20-6 and pA20-36
corresponding to the insert peptides of A20-1, A20-6 and A20-36 phage clones, respectively, showed a concentration-dependent binding to A20-Ig (Fig. 1A , middle panel), while testing negative for mouse polyclonal Igs (Fig. 1A, right panel) .
Competition of pA20-1, pA20-6 and pA20-36 for the same binding site of A20-Ig BCR was assessed by an inhibition assay (Fig S1C) . In this assay, the binding of N-biotinylated pA20-36 to A20-Ig was inhibited by increasing amounts of either unbiotinylated pA20-1, or pA20-6, albeit to a less extent as compared to the inhibition of unbiotinylated pA20-36, indicating that pA20-36, pA20-1 and pA20-6 bound to the same binding site with different affinities (Fig S1C) . The scrambled pCNT did not inhibit the binding of pA20-36 to A20-Ig (Fig. S1C ).
Flow cytometry analysis using FITC-conjugated peptides indicated that pA20-1, pA20-6 and pA20-36 bound specifically to A20 cells in a dose-dependent manner ( Fig. 1B and Fig. S1A and B). Due to the high affinity binding to A20 cells, the pA20-36 peptide was selected for further evaluation.
The molecular form of pA20-36 was assessed by mass spectrometry. MALDI-TOF analysis revealed that the peptide was present in its monomeric form, bearing an intramolecular disulfide bridge ( Fig S2) .
The binding affinity value of the A20-IgG:pA20-36 pair was 410 nM Kd as determined by surface plasmon resonance (SPR-Biacore) (Fig. 1C) . Further, the pA20-36 peptide and sA20-IgG colocalized at the A20 B cell surface by confocal microscopy (Fig. 1D ).
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Next, we tested whether the pA20-36 binding to sA20-Ig could induce calcium mobilization upon BCR signaling. The pA20-36 induced calcium fluxes in A20 cells, which were significantly increased by a tetrameric form of streptavidin-linked pA20-36 (Fig. S3A) ; scrambled pCNT peptide was ineffective.
As Ig-BCR engagement results in antigen uptake by BCR-mediated endocytosis 20 , we tested whether the binding of pA20-36 peptide to A20 cells could result in peptide internalization. The incubation of A20 cells with pA20-36 peptide resulted in peptide internalization upon 1 h incubation, as shown by confocal microscopy (Fig. S3B ). The kinetics of BCR-mediated internalization were similar in the case of anti-mouse IgG F(ab)' 2 and pA20-36 peptide (Fig. S3C ).
The degree of internalization was measured as the percentage of cells no longer expressing surface peptides, assuming T 50 as the time at which we observed 50% of BCR-IgG internalization. Despite a slight delay of pA20-36 internalization as compared to the F(ab)' 2 fragments (T 50 ~ 50' versus T 50 ~ 30'), similar kinetics and a complete internalization at three hours post-stimulation were observed in the case of the F(ab)'2 fragments and the pA20-36 peptide (Fig. S3C) . As previously reported 20 , the whole antibody was not internalized (Fig. S3C ).
Since crosslinking of the Ig-BCR results in growth-inhibiting signals that induced cell cycle arrest and apoptosis in B-cell lymphoma cells 21 , we tested whether the pA20-36 binding to A20 cells could affect cell division and apoptosis. To cross-link surface Ig-BCR, we used biotinylated peptides bound to tetravalent streptavidin 13, 14 . Cell viability was strongly impaired by in vitro incubation of A20 cells with either streptavidin-linked pA20-36, or anti-IgG F(ab')2 antibodies up to 72 h, while it was not significantly affected by monomeric pA20-36, pCNT or streptavidin-linked pCNT peptide ( Fig. 2A) . The cell cycle analysis showed that the monomeric pA20-36 treatment reduced the G2 population after 24-48 h, and significantly increased the sub-G1 cell population (apoptotic cells) (Fig. 2B, and Fig. S4A ). Moreover, the tetrameric pA20-36 treatment resulted either in a more consistent reduction of G2 population after 24-48 h, and in 4-5 fold increase of the For personal use only. on January 1, 2018. by guest www.bloodjournal.org From sub-G1 cell population at 48 h, as compared to the monomeric pA20-36. Consistently, the monomeric pA20-36 treatment resulted in a slight but significant increase of apoptosis, as assessed by Annexin-V binding, while it did not occur upon pCNT peptide treatment (Fig. 2C) , while the tetrameric pA20-36 treatment resulted in 4-5 fold increase of apoptotic cells compared to the monomeric pA20-36. Both monomeric and tetrameric pA20-36 treatments did not affect the growth of the 5T33MM cells (Fig. S4B) , a surface IgG-positive B cell line unable to bind to pA20-36 peptide (Fig. S1B ), thus ruling out that the apoptotic death triggered by pA20-36 was due to a non-specific toxic effect. The activity of the initiator caspase-9 activity was induced by pA20-36 at 24 h treatment followed by the activation of effector caspase-3/7 at 48 h, whereas caspase-8 activity was unaffected; these caspases were not activated by the scrambled pCNT peptide (Fig. 2D ).
Altogether, these results underscored that A20 tumor cells treated with pA20-36 peptide were driven toward a selective arrest of cell cycle at the G2 phase and a caspase-dependent apoptosis.
A20 B-lymphoma targeting in vivo by pA20-36.
To test the in vivo targeting ability of pA20-36, we used the A20 syngenic model of murine lymphoma 15, 16 . BALB/c mice were subcutaneously (s.c.) injected with A20 cells, and at day 12 peptides, as a tracer 22 . Since A20 tumor cells release the A20-Ig paraprotein, we first determined the concentration of serum A20-Ig, which might bind to pA20-36 peptide and prevent its binding to A20 cells. To this end, we developed a sensitive ELISA, which detected serum A20-Ig concentrations up to 0.1 ng/ml (Fig. S6A ). In A20 tumor engrafted mice, serum A20-Ig levels ranged between 8-17 ng/ml at day 7 (tumors undetectable by palpation; n=3), and 3.5-15.1 μg/ml at day 12 (tumor volume 63±39 mm 3 n=3) ( ) for two weeks. Both vehicle-or peptides-treated mice showed normal levels of the inflammatory cytokine IL1-β, and the hepatotoxicity marker GSH and LDH (Table 2) . (Fig. S8B) ; the nucleotide sequence overlapped with the one expressed by the original A20 cell clone 24 , indicating that the minimal residual disease observed in pA20-36-treated mice did not result from mutant, idiotypic escape of tumor IgG at day 24 post-treatment.
To address the mechanism of tumor growth inhibition by pA20-36, we analyzed the levels of apoptosis in pA20-36-treated tumor tissues. Flow cytometry of single tumor cell suspensions showed a statistically significant, higher number of Annexin V-positive cells in pA20-36-treated mice as compared to pCNT-treated mice at day 23 ( Fig. 4C) . Accordingly, the histology of fresh
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From tumor masses confirmed the presence of large areas of apoptotic cells in pA20-36-treated tumors, which were undetected in tumor treated with pCNT (Fig. 4D) . To analyze the effect of pA20-36 on apoptosis in vivo, syngenic BALB/c mice were i.p. injected with CFSE-labeled A20 tumor cells. At day three post-inoculation, mice were i.p. injected with pA20-36 or control peptide (100 μg/100 μl PBS), and 6 hr later single cell suspensions were isolated from lymph nodes. We observed a significant increase of sub-G1 DNA content in mice inoculated with pA20-36 as compared to control mice (Fig. 4E left) . Control CFSE-labeled 5T33MM cells were not significantly affected by the pA20-36 peptide treatment (Fig. 4E right) , indicating that pA20-36 specifically induced apoptosis of A20 B cells in vivo.
Analysis of tumor microenvironment.
Next, we addressed the impact of the Id-peptide treatment on anti-tumor immunity within the tumor microenvironment of the A20 B lymphoma-engrafted mice. First, we evaluated the expression levels of cytokines in tumor tissues by real time PCR of mRNAs. The pA20-36 treatment resulted in a reduced expression of immunosuppressive cytokines genes (Tgf-β and Il-10), and proangiogenic genes (VEGF, Thromboxane synthase) in the B-cell lymphoma-engrafted mice, while no significant effect was observed in the case of Ifn-γ (Fig. 5A) . The immunosuppressive cytokines IL-10 and TGF-β promote the development and activity of Foxp3 + CD4 + regulatory T (Treg) cells 25 ;
consistently with the reduced expression of IL-10 and TGF-β, Foxp3 expression was reduced in pA20-36-treated mice (Fig. 5A) , indicating that the pA20-36-treatment could affect the number of tumor infiltrating Treg cells.
The reduced expression of pro-angiogenic cytokines in tumor tissues from pA20-36-treated mice was investigated by assessing the outcome of pA20-36 treatment on tumor angiogenesis.
Immune fluorescence analysis using anti-CD31 MAb as marker of endothelial cells revealed a 25%
reduction of the micro-vessel density in tumor tissues of pA20-36-treated mice, as compared to (Fig. 5B and C) . Altogether, these results indicated that the decreased expression of pro-angiogenic cytokines in pA20-36-treated tumors resulted in reduced tumor angiogenesis. (Fig. 6A) . The pA20-36 treatment also decreased the number of CD4 + , CD8 + T and
Treg cells (Fig. 6A) . Tumor infiltrating CD8 + T cells expressed lower levels of the negative co-stimulatory molecules CTLA4 and PD-1 in pA20-36-treated mice as compared to pCNT-treated mice; CD62L, a marker of naïve and central memory T cells 27 , was also down-regulated in pA20-36-treated mice (Fig. 6C, upper panels) . Differently, tumor infiltrating CD4 + T cells showed similar expression levels of CTLA4, PD-1 and CD62L in pA20-36-and pCNT-treated mice (Fig. 6C, lower panels) .
These findings indicated that tumor tissues from pA20-36-treated mice were infiltrated by activated CD8 + T cells. Consistently, CD8 + granzyme B + T cells were selectively detected in tumor tissues of pA20-36-treated mice ( Fig. 6D and Fig. 7A ).
For (Fig. 7B) .
Next, we investigated the cytolytic activity of tumor infiltrating CD8 + T cells. The CD8 + T cells isolated from pA20-36-treated mice showed a dose-dependent killing activity against cultured A20 cells, whereas they did not significantly react against 5T33MM control cell line (Fig. 7C) .
Conversely, CD8 + T cells from pCNT-treated mice showed a weak cytolytic activity against both A20 and 5T33MM cells, which indicated the level of non-specific bystander effect (Fig. 7C) .
Collectively, these results show that tumor infiltrating CD8 + T cells from mice treated with pA20-36 elicited an effective immune response toward A20 tumor antigens in vitro. (Fig. 7D, left panel) . In pA20-36-treated groups of mice, we observed a further significant increase of tumor growth in CD8 + T cell-depleted mice, as compared to un-depleted mice (Fig. 7D , right panel), pointing to a relevant contribution of CD8 + T lymphocytes to the antitumor activity of the pA20-36 peptide. MicroPET analysis (Fig. 3) .
The in vitro functional analysis of the Id-peptide used in this study underscores some relevant activities: a) the pA20-36 Id-peptide was specifically internalized by target cells with a kinetic shared with the surface A20-Ig upon BCR cross-linking, suggesting a mechanism of receptormediated endocytosis (Fig. S3) ; b) the pA20-36 Id-peptide triggered a BCR-mediated signalling that induced apoptosis of the target cells (Fig. 2) . Accordingly, B cell apoptosis is observed in various types of both immature and mature neoplastic B cells following cross-linking of the sIg-BCR with surrogate antigens 29 . Moreover, effective immunotherapy of B-cell lymphoma based on passive transfer of Id-specific monoclonal antibodies correlated with anti-idiotype induced signal transduction in lymphoma cells 30 . The apoptotic pathway activated upon BCR-cross-linking has not been univocally clarified 31 ; however, evidence for mitochondria as central executors of BCRinduced apoptosis, and caspases-2, -3, and -9 as effectors of the apoptotic program downstream of mitochondria was reported [32] [33] [34] . Our results indicate that the BCR oligomerization by multimeric presentation of Id-peptide, recruited the apoptosis-initiating protease caspase-9, which in turn activated the executioner proteases caspase-3 and -7, thus resulting in apoptotic cell death of the targeted tumor cells (Fig. 2D) . Of interest, we also observed a significant apoptotic effect in vivo in the case of the monomeric Id-peptide (Fig. 4) , suggesting that pA20-36 could acquire both monomeric and multimeric conformations. Although this possibility needs to be further investigated, previous studies have shown that receptor peptide ligands can mediate the dimerization of the cognate receptors; in support of this possibility, the crystal structure of a 20-residue cyclic mimetic peptide of erythropoietin (EPO) revealed a simple, compact homo-dimer of β-hairpin structure that induced cross-linking of the EPO receptor, resulting in signal transduction and cell proliferation 35 .
Although cell apoptosis induced by chemotherapy or radiotherapy has been associated with a silent or tolerogenic immune response, recent studies have underscored the immunogenic properties of apoptotic cell death induced by chemotherapeutic compounds [36] [37] [38] . In this study, we report that an A20 cell-specific Id-peptide induced a consistent anti-tumor immunity in immune competent mice harboring A20 B lymphoma cells. Indeed, we observed an increased number of armed CD8 + T cells that colonized the tumor masses in pA20-36-treated mice ( Fig. 6D and 7A) . Consistently, CD8 + T cells showed an A20 cell-specific proliferative and cytolitic activity ( Fig. 7B and 7C) . Consistently, the CD8 + T cell depletion in mice strongly counteracted the tumor inhibition by pA20-36, thus pointing to the relevant role for CD8 + T cells in the mechanism of tumoricidal activity mediated by pA20-36 in vivo.
B-cell malignancies may present tumor antigen to the immune system by either a direct presentation 39, 40 , or by cross-presenting tumor antigens from apoptotic cells 41 . We observed that in vivo exposure of tumor cells to pA20-36 resulted in up-regulation of the co-stimulatory molecules CD80, CD86, and CD40 (Fig. 6B) , which was restricted to the tumor microenvironment, since their expression on A20 cells upon in vitro stimulation with pA20-36 was unaffected (Fig. S9 ). These (Fig.3) .
Of clinical interest, the selected idiotype peptide also exerted an effective killing activity in vivo.
A major limitation of the Id-peptide-based approach is the requirement of a panning procedure for each individual patient. However, there is evidence that chronic antigenic stimulation may contribute to the neoplastic transformation and drives a selective process that shapes the antigenic repertoire of a subset of B-cell proliferation, including CLL 47 . In this setting, Id-peptides will provide a unique tool to define the antigenic specificities of the Igs isolated from tumor B-cells and may devise an effective peptide-based strategy.
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